Clinical Trial Update: Sacituzumab Tirumotecan (MK-2870) Versus Pemetrexed and Carboplatin Combination Therapy in Participants With Epidermal Growth Factor (EGFR)-Mutated, Advanced Nonsquamous Non-small Cell Lung Cancer (NSCLC) Who Have Progressed on Prior EGFR Tyrosine Kinase Inhibitors (MK-2870-009) [Phase 3]

View source ↗

Summary

A Phase 3 trial comparing Sacituzumab Tirumotecan versus pemetrexed plus carboplatin in EGFR-mutated, advanced nonsquamous non-small cell lung cancer after prog…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Alimta (pemetrexed)
• CARBOPLATIN (Carboplatin)
• Sacituzumab Tirumotecan (Sacituzumab govitecan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Non-small Cell Lung Cancer (NSCLC) | Phase 3 | Status: RECRUITING